Patents Assigned to University of Miyazaki
-
Patent number: 11827667Abstract: [Problem] To develop a technique that can stabilize the higher-order structure of a nucleic acid and can be used in analysis of nucleic acid structure. [Solution] This guanosine derivative compound is represented by formula 1. In the formula, one of R1 and R2 represents H, and the other represents any of H, OH, OCH3, and F, R3 represents a functional group that is for detection and that has 19F, R4 represents an amine-protecting group, R5 represents a hydroxy group-protecting group, and R6 represents an introduction group that is to be introduced into a nucleic acid oligomer. This guanosine derivative compound can be introduced as a part of a nucleic acid sequence, and the introduced nucleic acid oligomer stabilizes the higher-order structure in a nucleic acid, and enables dynamic detection by 19F NMR.Type: GrantFiled: August 29, 2019Date of Patent: November 28, 2023Assignee: UNIVERSITY OF MIYAZAKIInventors: Yan Xu, Takumi Ishizuka, Hong-Liang Bao
-
Publication number: 20230321196Abstract: The present invention provides a means for preventing and/or treating a symptom of a viral infection in a subject affected by the viral infection without inducing any undesired serious side effect by optimizing the application method and the dose of a medicine containing AM or a derivative thereof as an active ingredient. One aspect of the present invention relates to a medicine for preventing or treating a symptom or disorder in a subject affected by a viral infection, the medicine containing adrenomedullin or a derivative thereof as an active ingredient.Type: ApplicationFiled: September 8, 2021Publication date: October 12, 2023Applicant: University of MiyazakiInventors: Kazuo Kitamura, Toshihiro Kita
-
Publication number: 20230243835Abstract: An adenocarcinoma detection method based on a protein fragment of WFDC2 protein in a sample originating from a subject, the method comprising determining a presence of adenocarcinoma by comparing a first determination value and a threshold value set in advance, the first determination value being a value derived by dividing a first fragment quantity, which is a quantity of a protein fragment having an amino acid sequence of SEQ ID NO: 1 in the sample as determined by an ELISA method, by a reference quantity defined by a total quantity of WFDC2 protein or a creatinine concentration in the sample as determined by an ELISA method.Type: ApplicationFiled: June 22, 2021Publication date: August 3, 2023Applicants: MITSUI CHEMICALS, INC., OSAKA UNIVERSITY, UNIVERSITY OF MIYAZAKIInventors: Komako ISHIKAWA, Koh AMANO, Toshifumi TAKAO, Nobuaki OKUMURA, Toshiki TAKEI, Masamitsu NAKAZATO, Hironobu TSUBOUCHI
-
Publication number: 20230174607Abstract: The invention provides novel adrenomedullin analogs that exhibit high biological stability in administering to subjects while maintaining pharmacological effects of the parent compound adrenomedullin.Type: ApplicationFiled: April 2, 2021Publication date: June 8, 2023Applicant: University of MiyazakiInventor: Kazuo Kitamura
-
Publication number: 20230154023Abstract: In a configuration in which an image acquisition unit that acquires an image of an animal, a shape identification unit that identifies a shape of a predetermined portion of the animal from the image, an information generation unit that, on a basis of the shape of the predetermined portion, generates estimation information used for estimating a weight of the animal, and a weight estimation unit that estimates the weight on a basis of the estimation information are provided, the information generation unit is capable of generating the estimation information both in a case where a first image (an animal image GA) in which the animal is imaged from a first direction is acquired and in a case where a second image in which the animal is imaged from a second direction that is different from the first direction is acquired.Type: ApplicationFiled: February 16, 2021Publication date: May 18, 2023Applicant: UNIVERSITY OF MIYAZAKIInventor: Kikuhito KAWASUE
-
Publication number: 20230142095Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: October 4, 2022Publication date: May 11, 2023Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Publication number: 20230120030Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal amino group of the peptide moiety B, or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: July 29, 2022Publication date: April 20, 2023Applicant: University of MiyazakiInventors: Kazuo Kitamura, Johji Kato, Keishi Kubo, Kenji Kuwasako, Shigeru Kubo, Kumiko Kumagaye
-
Patent number: 11578112Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient. A-L-B??(I).Type: GrantFiled: March 29, 2018Date of Patent: February 14, 2023Assignee: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki, Sayaka Nagata
-
Patent number: 11478551Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 29, 2020Date of Patent: October 25, 2022Assignee: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 11435354Abstract: There is provided a simple and minimally invasive adenocarcinoma detection method. The adenocarcinoma detection method of the present invention includes a step of detecting in vitro a presence or absence of an abnormal cleavage in a specific protein in a test subject-derived sample. The abnormal cleavage in the specific protein is, for example, a cleavage resulting in one or more breaks in a peptide bond in the specific protein and/or a cleavage resulting in a deletion of one or two more amino acid residues at one or more sites of the specific protein. The adenocarcinoma detection method of the present invention includes a step of detecting a presence or amount of a protein having the abnormal cleavage or a decrease in an amount of a normal protein.Type: GrantFiled: February 16, 2017Date of Patent: September 6, 2022Assignees: UNIVERSITY OF MIYAZAKI, OSAKA UNIVERSITYInventors: Masamitsu Nakazato, Nobuhiro Matsumoto, Yasuji Arimura, Hironobu Tsubouchi, Toshifumi Takao, Nobuaki Okumura, Masafumi Fukuda
-
Patent number: 11414474Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal amino group of the peptide moiety B, or a salt thereof, or a hydrate thereof.Type: GrantFiled: March 20, 2015Date of Patent: August 16, 2022Assignee: University of MiyazakiInventors: Kazuo Kitamura, Johji Kato, Keishi Kubo, Kenji Kuwasako, Shigeru Kubo, Kumiko Kumagaye
-
Patent number: 11413654Abstract: Provided is an ultrasonic vibration processing device which can suppress vibration of components due to an ultrasonic vibrator and can perform processing using ultrasonic vibration in a preferable manner; the ultrasonic vibration processing device includes: a housing (10); an ultrasonic vibrator (20) including a horn portion (21A) to which a tool holder (70) is detachably attached and a piezoelectric element (23), the ultrasonic vibrator having a rear end located at a node of ultrasonic vibration and being supported inside the housing (10) so as to be rotatable; a connecting portion (30) stored in the housing (10) so as to be rotatable together with the ultrasonic vibrator (20); a motor (40) connected to the connecting portion (30); and a non-contact power supply unit (50) including a primary transformer (51) and a secondary transformer (52), the primary transformer (51) being fixed to the housing (10) and including a primary coil (51B) that receives high frequency power from an external power supply, the secType: GrantFiled: July 17, 2018Date of Patent: August 16, 2022Assignees: KIRA CORPORATION, UNIVERSITY OF MIYAZAKI, THE UNIVERISITY OF KITAKYUSHUInventors: Hiromichi Onikura, Osamu Ohnishi, Hiroshi Murakami
-
Publication number: 20220213495Abstract: A method for producing a microbial oil includes the steps of: genetically modifying a labyrinthulid by disrupting and/or silencing a gene, or by transforming another gene in addition to the disruption and/or gene silencing of the gene; culturing the labyrinthulid, such that a fatty acid composition accumulated in the labyrinthulid comprises an increased EPA content; and collecting the microbial oil having the increased EPA content from the labyrinthulid. The increased EPA content is not less than 3.3% of a total fatty acid composition.Type: ApplicationFiled: November 15, 2021Publication date: July 7, 2022Applicants: KYUSHU UNIVERSITY, NAT'L UNIVERSITY CORPORATION, UNIVERSITY OF MIYAZAKI, KONAN GAKUEN, NIPPON SUISAN KAISHA, LTD.Inventors: Keishi Sakaguchi, Rie Hamaguchi, Takanobu Matsuda, Makoto Ito, Naoki Nagano, Masahiro Hayashi, Yuji Okita, Shinichi Sugimoto, Daisuke Honda
-
Publication number: 20210115103Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient.Type: ApplicationFiled: March 29, 2018Publication date: April 22, 2021Applicant: UNIVERSITY OF MIYAZAKIInventors: Kazuo KITAMURA, Motoo YAMASAKI, Sayaka NAGATA
-
Publication number: 20210008219Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: September 29, 2020Publication date: January 14, 2021Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 10842879Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 16, 2016Date of Patent: November 24, 2020Assignee: UNIVERSITY OF MIYAZAKIInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 10815505Abstract: A microbial oil is extracted from stramenopile transformed with a gene associated with synthesis of fatty acids, the gene encoding a fatty acid desaturase. The stramenopile belongs to the class Labyrinthulomycete. The microbial oil satisfies one or more of the following requirements: (a) an amount of arachidonic acid is 7% or less based on a total amount of the fatty acid composition; (b) an amount of DPA is 9% or less based on the total amount of the fatty acid composition; (c) an amount of ETA is 0.04% or more based on the total amount of the fatty acid composition; (d) an amount of EPA is 7% or more based on the total amount of the fatty acid composition; and (e) an amount of DHA is 45% or more based on the total amount of the fatty acid composition.Type: GrantFiled: February 1, 2018Date of Patent: October 27, 2020Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, UNIVERSITY OF MIYAZAKI, Konan Gakuen, NIPPON SUISAN KAISHA, LTD.Inventors: Keishi Sakaguchi, Takanori Matsuda, Takumi Kobayashi, Makoto Ito, Naoki Nagano, Masahiro Hayashi, Daisuke Honda, Yosuke Taoka, Yuji Okita, Hitoshi Izumida, Shinichi Sugimoto
-
Publication number: 20200180041Abstract: Provided is an ultrasonic vibration processing device which can suppress vibration of components due to an ultrasonic vibrator and can perform processing using ultrasonic vibration in a preferable manner.Type: ApplicationFiled: July 17, 2018Publication date: June 11, 2020Applicants: KIRA CORPORATION, UNIVERSITY OF MIYAZAKI, THE UNIVERISITY OF KITAKYUSHUInventors: Hiromichi ONIKURA, Osamu OHNISHI, Hiroshi MURAKAMI
-
Patent number: 10431831Abstract: A catalyst particle is composed of an inner particle and an outermost layer that includes platinum and covers the inner particle. The inner particle includes on at least a surface thereof a first oxide having an oxygen defect.Type: GrantFiled: April 13, 2017Date of Patent: October 1, 2019Assignees: Toyota Jidosha Kabushiki Kaisha, University of MiyazakiInventors: Go Sakai, Tatsuya Arai, Tetsuya Ogawa, Koshi Sekizawa, Naoki Takehiro
-
Patent number: 10335455Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.Type: GrantFiled: March 3, 2017Date of Patent: July 2, 2019Assignee: University of MiyazakiInventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita